logo
  

China Housing & Land Development Terminates "going Private" Transaction

China Housing & Land Development Inc. (CHLN), a developer of residential and commercial properties in northwest China, announced that the board of directors of the Company has resolved to terminate the "going private" transaction authorized and approved by the Board on August 19, 2014.

The company noted that the proposed Transaction was terminated as a result of changing financial, operational and business conditions. Given the ongoing trend in China's real estate market, the Board felt it was important for the Company to maintain a more conservative financial position and focus on supporting current and planned projects.

In August, China Housing & Land Development has said that its board authorized and approved a "going private" transaction, for eliminating CHLN's status as a public company in the U.S.

The transaction would include a reverse stock split shares of the company's common stock, whereby every 50,000 shares of the common stock issued and outstanding will be converted into one whole share of the company's common stock. The company said it would make a cash payment equal to $1.75 per pre-reverse stock split share to such stockholders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT